The state of Arizona currently has 12 active clinical trials seeking participants for Epilepsy research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa.
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/24/2025
Locations: Barrow Neurological Institute, Phoenix, Arizona +2 locations
Conditions: Generalized Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/23/2025
Locations: Barrow Neurological Institute, Phoenix, Arizona +1 locations
Conditions: Focal Epilepsy
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Recruiting
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/23/2025
Locations: Xenoscience, Inc., Phoenix, Arizona +1 locations
Conditions: Focal Epilepsy
Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
Recruiting
The study involves up to 5 visits for a fasting blood draw, behavioral assessments, and/or questionnaires. Other samples may be collected when appropriate. This study is currently recruiting. There is no cost for visits or study-related exams.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
12/23/2024
Locations: Southwestern Research and Resource Center, Phoenix, Arizona
Conditions: Autism Spectrum Disorder, Mitochondrial Pathology, Epilepsy, Brain Tumor, Psychiatric Disorder, Mitochondrial Diseases
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures
Recruiting
The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
12/17/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Partial Epilepsy
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
12/16/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Partial Epilepsy
Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)
Recruiting
The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona
Conditions: Epilepsy
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
Recruiting
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse even... Read More
Gender:
ALL
Ages:
9 years and above
Trial Updated:
11/14/2024
Locations: Barrow Neurological Institute, St. Joseph's Hospital & Medical Center, Phoenix, Arizona
Conditions: Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Epilepsy Learning Healthcare System (ELHS)
Recruiting
The Epilepsy Learning Health System (ELHS) is a quality improvement and research network to improve outcomes for people with epilepsy. The ELHS is designed as a model of value-based chronic care for epilepsy as envisioned by the National Academies of Medicine Committee in their landmark reports "The Learning Health System" and "Epilepsy Across the Spectrum: Promoting Health and Understanding". The ELHS network is a collaboration among clinicians, patients and researchers that promotes the use o... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/28/2024
Locations: Barrow Neurological Institute Comprehensive Epilepsy Center, Phoenix, Arizona
Conditions: Epilepsy, Seizure Disorder, Neurologic Disorder, Rare Diseases
FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
Recruiting
This clinical trial is designed to test whether a single stereotactic intracerebral administration of inhibitory nerve cells into subjects with drug-resistant mesial temporal lobe epilepsy is safe (frequency of adverse events) and effective (seizure frequency).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/11/2024
Locations: Mayo Clinic Arizona Epilepsy Center, Phoenix, Arizona +1 locations
Conditions: Mesial Temporal Lobe Epilepsy With Hippocampal Sclerosis
Safety and Efficacy of tPBM for Epileptiform Activity in Autism
Recruiting
For this study, the proposed intervention will be noninvasively delivered near infra-red (NIR) light - transcranial Photobiomodulation (tPBM) - to the brains of autistic children. This will occur, twice a week, for 10 weeks. The NIR light is delivered to specific brain areas by Cognilum, a wearable device developed by Jelikalite. The expected outcome is improved focus, improved eye contact, improved speech, improved behavior, and gains in functional skills. Cognilum may impact the clinical pract... Read More
Gender:
ALL
Ages:
Between 4 years and 12 years
Trial Updated:
07/08/2024
Locations: Rossignol Medical Center, Phoenix, Arizona
Conditions: Autism Spectrum Disorder, EEG With Periodic Abnormalities, Epilepsy, Neurodevelopmental Disorders, Neurological Disorder
Patterns of Neurodevelopmental Disorders
Recruiting
The purpose of this study is to systematically evaluate the results of medical investigations to identify symptom and biological patterns and common etiologies of neurodevelopmental disorders.
Gender:
All
Ages:
All
Trial Updated:
03/22/2024
Locations: Rossignol Medical Center, Phoenix, Arizona
Conditions: Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency